Panelists will explore the current state of cannabis legalization in various regions throughout the Americas and highlight emerging markets with high growth potential. Attendees will leave this panel with a deeper understanding of the current state and future potential of emerging cannabis markets in the Americas, as well as insights and strategies for success in these exciting and rapidly evolving markets.
This program is eligible for 1 hours of General CLE credit in 60-minute states, and 1.2 hours of General CLE credit in 50-minute states. Credit hours are estimated and are subject to each state’s approval and credit rounding rules.
INCBA webinars are generally eligible for credit in the following states: AR, AL, CA, CO, GA, HI, IL, NJ, NM, NY, ND, PA, TX, VT. Additional states may be available for credit upon self-application by attendees. States typically decide whether a program qualifies for MCLE credit in their jurisdiction 4-8 weeks after the program application is submitted. For many live events, credit approval is not received prior to the program.
The on-demand version of this webinar is eligible for credit in the following states: AR, AL, CA, CO, GA, HI, IL, NJ, NM, NY, ND, PA, TX, VT. Additional states may be available for credit upon self-application by attendees.
(Default credit disclaimer updated 02.08.2024)
For current accreditation status, please select your jurisdiction below.
CLI Costa Rican Hemp-Cannabis Production Legal Summary 05152023.pdf
(264.9 KB)
CLI Costa Rican Hemp-Cannabis Production Legal Summary 05152023.pdf |
Available after Purchase |
CLI LATAM Additional Supporting Information.pdf
(182.2 KB)
CLI LATAM Additional Supporting Information.pdf |
Available after Purchase |
OUTLINE - CLI LatAm Market.pdf
(70.9 KB)
OUTLINE - CLI LatAm Market.pdf |
Available after Purchase |
CLI LA Emerging Canna Market - Read-Only (002).pptx
(6.8 MB)
CLI LA Emerging Canna Market - Read-Only (002).pptx |
Available after Purchase |
Partner of Carey and co-head of the firm’s Life Sciences and Biotechnology and Public Law Groups. His practice focuses on life sciences, biotechnology and public law, advising companies on intellectual property issues related to the pharmaceutical industry, cosmetics, medical devices, commercialization and advertisement of these products, scientific research, clinical studies, regulation of medical professions, privacy, data protection, public and private procurement and biddings, licenses, distribution and franchises. He also represents clients in administrative processes and in sanitary, administrative and judicial litigation derived from those operations.
Ingrid Ortiz joined OLIVARES in 2011. She studied law at Monterrey Institute of Technology and Advanced Studies (by its acronym in Spanish “ITESM”, Tecnológico de Monterrey) in Mexico City.
Ingrid is member of the Life Sciences & Pharmaceutical law at OLIVARES. Her practice is mainly focused on Intellectual Property Litigation, Regulatory and Administrative Litigation; as well as Regulatory and Compliance advisory. Her main areas of practice allow her to interact with the Mexican sanitary agency, the Federal Commission for Protection against Sanitary Risks (by its acronym in Spanish “COFEPRIS”), the Mexican Patent and Trademark Office (by its acronym in Spanish “IMPI”), and the Courts of law, such as the Federal Court of Tax and Administrative Affairs, the Federal District Courts and the Federal Circuit Courts.
Zayde has over 20 years of experience providing legal counseling for patents and plant variety protection, as well as conducting civil and administrative litigation of intellectual property rights. She has profound professional experience in two countries, and currently is one of the top patent advisors in Costa Rica with respect to both patent prosecution and plant variety protection. Zayde’s practice includes the filing of PCT patent applications for international and national phases, and the strategic planning for the protection of new plant varieties and prosecution of PBR rights. Zayde also has extensive experience with the protection of industrial property in the framework of the regulatory procedures necessary for the health registration of medicines, such as data exclusivity protection and linkage.